25-Apr-2016 — CSL was established in 1916 by the Australian Government to ensure an isolated nation had reliable access to therapeutic sera, vaccines and other life-saving biological products during times of war and other global threats.
14-Apr-2016 — As an Australian company and global leader in developing medicines for rare and serious disease, CSL is uniquely placed to demonstrate to young people the difference they can make to human health through a career in the sciences.
Other recent news:
14-Apr-2016 — CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia. More.
07-Mar-2016 — The University of Melbourne’s internationally recognized Bio21 Molecular Science and Biotechnology Institute is to be substantially expanded and will house CSL’s Global Research and Translational Medicine Hub. More.
07-Mar-2016 — CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. More.